Controlled ultrasonic interventions through the human skull.
Authors: Wilson MG, Riis TS, Kubanek J
Transcranial focused ultrasound enables precise and non-invasive manipulations of deep brain circuits in humans, promising to provide safe and effective treatments of various neurological and mental health conditions. Ultrasound focused to deep brain targets can be used to modulate neural activity directly or localize the release of psychoactive drugs. However, these applications have been impeded by a key barrier-the human skull, which attenuates ultrasound strongly and unpredictably. To address this issue, we have developed an ultrasound-based approach that directly measures and compensates for the ultrasound attenuation by the skull. No additional skull imaging, simulations, assumptions, or free parameters are necessary; the method measures the attenuation directly by emitting a pulse of ultrasound from an array on one side of the head and measuring with an array on the opposite side. Here, we apply this emerging method to two primary future uses-neuromodulation and local drug release. Specifically, we show that the correction enables effective stimulation of peripheral nerves and effective release of propofol from nanoparticle carriers through an <i>ex vivo</i> human skull. Neither application was effective without the correction. Moreover, the effects show the expected dose-response relationship and targeting specificity. This article highlights the need for precise control of ultrasound intensity within the skull and provides a direct and practical approach for addressing this lingering barrier.
Introduction
Purpose
Transcranial ultrasound stimulation
Study Objective
Develop and demonstrate an ultrasound-based method that directly measures and compensates for skull attenuation to enable effective transcranial neuromodulation and localized drug release.
Animal model / Human subject
Homo sapiens (ex vivo human skull); strain: N/A; age: 21-39 years old; sex: 3 female, 8 male
MRI or image guidance method
Hydrophone-assisted acoustic field mapping
Cargo name and characteristics
Propofol — a small-molecule anesthetic released from drug-loaded nanoparticle carriers
Outcomes and Safety
Summary of Outcomes
Attenuation-compensated transcranial focused ultrasound delivered across an ex vivo human skull enabled effective peripheral nerve stimulation and targeted release of propofol from nanoparticle carriers, with observed dose–response and targeting specificity. These effects were not observed without skull-attenuation correction
Safety-related matter
The authors describe transcranial focused ultrasound as promising to provide safe and effective, non-invasive treatments and emphasize the need for precise control of ultrasound intensity; no adverse effects are reported or mentioned in the text.
Brain Region
Ultrasound Parameters
Ultrasound instrument
Two spherically focused 126-element ultrasound array driven by a Verasonics Vantage 256 system
FUS Frequency
650 kHz
FUS Pressure
1.3-1.8 Mpa
FUS Mode
pulsed
Pulse duration
100 ms
Duration of a single FUS session
60 s
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: None
Treatment frequency
Single
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search